ProPhase Labs, Inc. Effective Tax Rate
ProPhase Labs, Inc. (PRPH) reported Effective Tax Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-06-01
- ProPhase Labs, Inc. effective income tax rate reconciliation, percent for the quarter ending 2024-03-31 was 28.66%, a 1595.86% increase year-over-year.
- ProPhase Labs, Inc. effective income tax rate reconciliation, percent for the quarter ending 2023-03-31 was 1.69%, a 92.13% decline year-over-year.
- ProPhase Labs, Inc. effective income tax rate reconciliation, percent for the quarter ending 2022-03-31 was 21.47%.
- ProPhase Labs, Inc. effective income tax rate reconciliation, percent for fiscal 2025 was 0.00%.
- ProPhase Labs, Inc. effective income tax rate reconciliation, percent for fiscal 2024 was -20.40%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-06-01 | |||
| 2024-12-31 | -20.40% 10-K · filed 2026-06-01 | |||
| 2024-09-30 | 28.00% 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 28.10% 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 28.66% 10-Q · filed 2024-05-10 | |||
| 2023-09-30 | 27.88% 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 34.96% 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | 1.69% 10-Q · filed 2023-05-12 | |||
| 2022-09-30 | 25.57% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 24.24% 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | 21.47% 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |